Physician profile
Douglas Kast
NPI 1144471798
$20,128.79
in general payments reported to CMS, 2019-2025
62 companies · $6,760 in 2025
The $6,760 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,996 · 2020: $1,481 · 2021: $2,111 · 2022: $3,117 · 2023: $2,424 · 2024: $2,239 · 2025: $6,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,332 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,080 · Travel and Lodging: $11.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,331.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,080.00 |
| Travel and Lodging | $11.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,187.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $2,221.93 | 2019-2025 | |
| Novo Nordisk INC | $1,475.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,246.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,150.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,135.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $599.30 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $537.21 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $386.05 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $384.65 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $331.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.31 | 2019-2024 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $298.40 | 2021-2025 | |
| Abbott Laboratories | $278.07 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $260.51 | 2020-2023 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Kast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.